Milford Funds Ltd. Purchases New Stake in Haleon PLC Sponsored ADR $HLN

Milford Funds Ltd. purchased a new stake in Haleon PLC Sponsored ADR (NYSE:HLN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 180,000 shares of the company’s stock, valued at approximately $1,820,000.

Several other institutional investors have also recently added to or reduced their stakes in HLN. Stance Capital LLC acquired a new stake in Haleon in the third quarter valued at $34,000. Geneos Wealth Management Inc. raised its holdings in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after acquiring an additional 1,203 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Haleon by 428.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock valued at $57,000 after acquiring an additional 5,124 shares in the last quarter. Assetmark Inc. raised its holdings in Haleon by 26.6% in the fourth quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock valued at $60,000 after acquiring an additional 1,252 shares in the last quarter. Finally, Atlantic Union Bankshares Corp raised its holdings in Haleon by 69.4% in the fourth quarter. Atlantic Union Bankshares Corp now owns 6,264 shares of the company’s stock valued at $63,000 after acquiring an additional 2,567 shares in the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Stock Up 1.1%

Shares of NYSE:HLN opened at $9.13 on Friday. The stock has a market capitalization of $40.45 billion, a price-to-earnings ratio of 23.42, a price-to-earnings-growth ratio of 2.06 and a beta of 0.13. Haleon PLC Sponsored ADR has a 1-year low of $8.65 and a 1-year high of $11.28. The company’s fifty day moving average is $9.34 and its two-hundred day moving average is $9.91. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92.

Haleon (NYSE:HLN) last issued its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The business had revenue of $3.65 billion for the quarter. Equities analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 EPS for the current year.

Wall Street Analysts Forecast Growth

HLN has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Argus raised shares of Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Finally, Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Haleon currently has an average rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.